Multiple Sclerosis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 31.03 Billion |
| Market Size (2029) | USD 37.52 Billion |
| CAGR (2024 - 2029) | 3.87 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Multiple Sclerosis Therapeutics Market Analysis
The Multiple Sclerosis Therapeutics Market size is estimated at USD 31.03 billion in 2024, and is expected to reach USD 37.52 billion by 2029, growing at a CAGR of 3.87% during the forecast period (2024-2029).
Multiple sclerosis (MS) affects cognitive, emotional, motor, sensory, and visual functions and is caused by the immune system attacking the brain and spinal cord. In recent years, the burden of multiple sclerosis has been observed to be on the rise, which is boosting the demand for therapeutic drugs for proper multiple sclerosis disease management. For instance, according to the August 2023 update of the World Health Organization (WHO), more than 2.8 million people globally are now estimated to live with MS, including 1 million in the United States in 2022. Thus, this escalating burden of multiple sclerosis will provide lucrative growth opportunities for the market during the forecast period.
Moreover, critical pharmaceutical companies invest significantly in drug development, such as MS therapeutics. They plan to target as many indications as possible to cater to the increasing demand for therapeutics. For instance, in October 2023, Tiziana Life Sciences received FDA approval for its drug candidate, foralumab. This intranasal anti-CD3 monoclonal antibody, a fully human formulation, is intended for at-home self-administration. It is designed for patients with multiple sclerosis (MS). Thus, the recent product approvals and increased efforts by pharmaceutical companies to develop novel therapeutics are leading to market expansion.
Additionally, an increase in research funding, grants, and other investments for developing multiple sclerosis research is projected to fuel the market growth during the forecast period. For instance, in December 2022, the United Kingdom initiated a groundbreaking trial to evaluate stem cell transplants as the primary treatment for multiple sclerosis. The StarMS study, funded at GBP 2.3 million (USD 2.91 million), is the first to compare the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) with four other drug treatments that have demonstrated positive results in clinical trials, which are alemtuzumab, ocrelizumab, ofatumumab, and cladribine. Therefore, an increase in clinical studies is expected to surge the introduction of novel products, thereby expanding the treatment options for multiple sclerosis.
Thus, owing to the increase in MS prevalence and various organic and inorganic activities of the key players, the market is expected to grow during the forecast period. However, side effects associated with medications and the high cost of drugs may hinder the market's growth.
Multiple Sclerosis Therapeutics Market Trends
The Oral Route of Administration Segment is Expected to Witness Rapid Growth During the Forecast Period
The oral route of administration segment is expected to witness significant growth during the forecast period owing to advantages like patient satisfaction and increased therapeutic compliance with the oral route compared to other routes. Further, a rise in product launches and approvals for drugs targeting MS in tablets or capsules will likely fuel market growth. For instance, in June 2022, Amneal Pharmaceuticals Inc. launched LYVISPAH, a United States FDA-approved granules (5, 10, and 20 mg) for managing spasticity related to multiple sclerosis (MS) and other spinal cord disorders. This launch helped the company to bolster its neurological disorders therapies in the US market.
Similarly, in June 2022, Sandoz expanded its portfolio by launching the generic drug Dimethyl fumarate HEXAL, approved for treating adults with relapsing-remitting multiple sclerosis (RRMS) in Germany. Dimethyl fumarate HEXAL enteric-coated hard capsules are a cost-effective alternative to the reference medicine Tecfidera in treating adult patients with multiple sclerosis. Thus, the rising product approvals and introduction of novel oral therapeutics for managing multiple sclerosis are pushing segment expansion.
Also, increasing pipeline studies and developments in multiple sclerosis will likely contribute to market growth. For instance, in October 2023, Bristol Myers Squibb presented data on Zeposia (ozanimod), focusing on its impact on the long-term disease progression and cognition of patients with relapsing forms of multiple sclerosis. Notably, 76% of patients who were administered Zeposia for relapsing multiple sclerosis (RMS) showed no signs of confirmed disability progression (CDP) over six months. Such positive outcomes in clinical trials and expected launches in the next 2-3 years are projected to contribute to segment expansion.
Due to the rise in product launches, approvals, and other strategic activities by key players, along with an increase in clinical studies in the field of multiple sclerosis (MS), this segment is expected to drive demand in the market during the forecast period.
North America is Expected to Hold a Significant Share During the Forecast Period
The market for multiple sclerosis therapeutics is expected to show healthy growth in North America, which is majorly attributed to the rising prevalence of multiple sclerosis and critical players focusing on the multiple sclerosis (MS) pipeline. Also, increased research funding and activities for treating MS are expected to bolster market growth. For instance, in November 2023, the National Multiple Sclerosis Society invested USD 4.4 million in new research projects, aligning with their strategy to guide global MS research toward promising areas outlined in the Pathways to Cures roadmap. This commitment is part of an annual investment exceeding USD 30 million in over 200 MS research studies globally.
Additionally, the presence of the key market player, the rise in product launches, and the approval by the regulatory authorities are propelling the market's growth. For instance, in December 2022, TG Therapeutics received the US FDA approval for BRIUMVI (ublituximab-xiiy) to treat relapsing forms of multiple sclerosis (MS). It is given in a one-hour infusion after the initial four-hour dose. It is one of the first anti-CD20 monoclonal antibodies approved in the United States for relapsing MS patients.
Moreover, the regional market is growing due to increased collaboration between pharmaceutical companies and governments to expand access to multiple sclerosis treatments. In April 2022, Novartis Pharmaceuticals Canada Inc. announced that Kesimpta (ofatumumab) is covered under Ontario's Exceptional Access Program (EAP) and included on the Régie de l'assurance maladie du Québec (RAMQ) list of medications as an exceptional medication for treating adults with relapsing-remitting multiple sclerosis (RRMS) with active disease features. This development enhances access to effective treatment for eligible patients in Quebec and Ontario.
Thus, the key players' increased product launches, approvals, and other strategic activities, coupled with the increase in the prevalence of MS in North America, are expected to bolster the demand in the market during the forecast period.
Multiple Sclerosis Therapeutics Industry Overview
The multiple sclerosis therapeutics market is moderately competitive, with few players. These big pharmaceutical companies focus on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, more companies may enter the market, and the competition may increase. Some major companies currently dominating the market are Biogen Inc., Novartis AG, Merck KGaA, Sanofi, and Acorda Therapeutics Inc.
Multiple Sclerosis Therapeutics Market Leaders
-
Biogen Inc.
-
Novartis AG
-
Merck KGaA
-
Sanofi S. A.
-
Acorda Therapeutics, Inc.
*Disclaimer: Major Players sorted in no particular order
Multiple Sclerosis Therapeutics Market News
- March 2024: Juvisé Pharmaceuticals, a French pharmaceutical company, acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod), indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS), from Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company (Johnson & Johnson).
- February 2024: Roche Pharma India launched the monoclonal antibody drug Ocrevus (ocrelizumab) as a disease-modifying therapy (DMT) for both relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in India.
Multiple Sclerosis Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Multiple Sclerosis across the World
4.2.2 Growing Focus of Companies on Pipeline Products for Multiple Sclerosis
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medication
4.3.2 High Cost of the Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD)
5.1 By Drug Type
5.1.1 Large-molecule Drugs
5.1.2 Small-molecule Drugs
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectable and Other Routes of Administration
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceuticals Industries Ltd
6.1.2 Novartis AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 Biogen
6.1.5 Bayer AG
6.1.6 Sanofi SA
6.1.7 Viatris Inc. (Mylan NV)
6.1.8 Merck KGaA
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Acorda Therapeutics Inc.
6.1.11 Johnson & Johnson Services Inc. (Janssen Global Services LLC)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Multiple Sclerosis Therapeutics Industry Segmentation
As per the scope of the report, multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system (CNS). The multiple sclerosis therapeutics market is segmented by drug type, route of administration, and geography. By drug type, the market is segmented into small-molecule drugs and large-molecule drugs. By route of administration, the market is segmented into oral, injectable, and other routes of administration. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
| By Drug Type | |
| Large-molecule Drugs | |
| Small-molecule Drugs |
| By Route of Administration | |
| Oral | |
| Injectable and Other Routes of Administration |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Multiple Sclerosis Therapeutics Market Research FAQs
How big is the Multiple Sclerosis Therapeutics Market?
The Multiple Sclerosis Therapeutics Market size is expected to reach USD 31.03 billion in 2024 and grow at a CAGR of 3.87% to reach USD 37.52 billion by 2029.
What is the current Multiple Sclerosis Therapeutics Market size?
In 2024, the Multiple Sclerosis Therapeutics Market size is expected to reach USD 31.03 billion.
Who are the key players in Multiple Sclerosis Therapeutics Market?
Biogen Inc., Novartis AG, Merck KGaA, Sanofi S. A. and Acorda Therapeutics, Inc. are the major companies operating in the Multiple Sclerosis Therapeutics Market.
Which is the fastest growing region in Multiple Sclerosis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Multiple Sclerosis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Multiple Sclerosis Therapeutics Market.
What years does this Multiple Sclerosis Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Multiple Sclerosis Therapeutics Market size was estimated at USD 29.83 billion. The report covers the Multiple Sclerosis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Multiple Sclerosis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Multiple Sclerosis Therapeutics Industry Report
The Multiple Sclerosis Treatment Market Report provides a comprehensive industry analysis, focusing on various aspects of the market, including market segmentation by drug type, route of administration, and geography. This industry report offers valuable market data and industry statistics, highlighting the market size and market value of the Multiple Sclerosis Therapeutics sector. The report also includes a market forecast, giving an industry outlook and market predictions up to the forecast period.
The industry research encompasses both large-molecule and small-molecule drugs, with further segmentation by oral, injectable, and other routes of administration. Geographical coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and South America, providing a detailed industry overview and market review for each region.
Key market trends and industry trends are analyzed, offering insights into the market growth and growth rate of the Multiple Sclerosis Therapeutics market. The report also identifies market leaders and provides a market overview, outlining the competitive landscape and market segmentation.
For those interested in detailed industry information, the report includes a sample of the industry analysis as a free report PDF download. This report example offers a snapshot of the comprehensive research conducted by Mordor Intelligence™ Industry Reports. The market research includes an analysis of market growth, market outlook, and industry sales, ensuring a thorough understanding of the market dynamics.
In summary, this report is an essential resource for research companies and stakeholders in the Multiple Sclerosis Treatment Market, providing in-depth industry reports, market forecast, and industry sales data. The report's industry information and market predictions make it a valuable tool for understanding the current and future state of the market.
Multiple Sclerosis Therapeutics Market Report Snapshots
